A Post-Marketing Observational Study (PMOS) to Determine the Effectiveness and Patient Satisfaction With Adalimumab Treatment in Patients With Rheumatoid Arthritis (PASSION Study)
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PASSION
- Sponsors Abbott Laboratories; AbbVie
Most Recent Events
- 24 Oct 2018 Results assessing the clinical outcomes across 4 regional areas for patients in this study according to patient support program participation, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 24 Oct 2018 Results assessing the the incidence of disease flare and the regain of disease control after flare among patients treated with adalimumab in this study according to patient support program participation, presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
- 16 Jun 2018 Results of subgroup analysis evaluating the impact of ADA in clinical, functional, and pt-reported outcome treatment targets and sustained responses by PSP use presented at the 19th Annual Congress of the European League Against Rheumatism